Document:

exv10w10

 

	 	 	 	 	 

LICENSE, MARKETING AND DISTRIBUTION AGREEMENT

This License, Marketing and Distribution Agreement (“Agreement”) is made effective as of March 7,
2008, among:

JUST-IN CASE FIRE LTD., an Alberta registered corporation (“Licensee”),

MOHSEN C. AMIRAN, PHD an individual resident in Illinois (“Amiran”),

SUMMIT ENVIRONMENTAL CORPORATION, INC., a Texas corporation (“Summit”); and

BIOGENESIS Enterprises Inc. an Illinois corporation (“BioGenesis”).

     WHEREAS, Amiran is a technical expert in physical organic chemistry and has invented, designed
and developed FlameOut, as hereinafter defined, the patent and intellectual property rights to
which are owned by Summit;

     WHEREAS, Licensee has developed an on-demand suppression system for suppressing fires using
self-contained, portable, mechanized equipment developed by Licensee in combination with chemical
formulations utilizing FlameOut;

     WHEREAS, BioGenesis currently manufactures FlameOut for Summit;

     WHEREAS, Licensee desires to exclusively develop certain markets and distribute FlameOut in
those markets; and

     WHEREAS, Summit is willing to grant to Licensee an exclusive license to market and distribute
FlameOut in certain defined territories they develop, and to grant the Licensee the limited right
to practice the FlameOut Patent for the purposes of preparing FlameOut for sale.

     NOW THEREFORE IN CONSIDERATION of the mutual covenants and agreements herein contained and for
other good and valuable consideration, the receipt and sufficiency of which is acknowledged by the
Parties hereto, the Parties agree as follows:

ARTICLE 1 INTERPRETATION

	1.1	 	Definitions

In this agreement:

“Affiliate” means: (i) any Person directly or indirectly controlling, controlled by or under common
control with said Person (including any partnership in which such Person serves as a general
partner, any corporation in which such Person owns greater than 5% of the issued and outstanding
voting capital stock or any limited liability company or joint venture in which such
Person owns greater than 5% of the equity interests); and (ii) any officer, director, trustee or

Exhibit 10.10
– Page 1

 

 

general partner of any Person so controlling, controlled by or under common control with said
Person.

“Business Day” means Monday through Friday, except a holiday designated by the federal government
of the United States as a national holiday.

“Effective Date” means March 7th, 2008.

“Flame Out” means the product produced from FlameOut Bulk by the Licensee, suitable for sale to
customers of the Licensee.

“FlameOut Patent” shall mean the formula and specifications related to US Patent 6296781 filed
October 2nd, 2001, and any improvements to such patent whether patentable or not.

“FlameOut Bulk” shall mean the bulk chemical agent manufactured by Summit and/or BioGenesis
according to the formula and specifications of the FlameOut Patent.

“Notice” means any notice, citation, directive, order, claim litigation, investigation, proceeding,
judgment, letter or other communication, written or oral, actual or threatened, from any Person.

“Parties” means all of the parties to this Agreement and “Party” means any one of them.

“Person” means any individual, partnership, joint venture, limited liability company, corporation,
trust, unincorporated entity, association, sole proprietorship or other entity, including any such
entity controlled, directly or indirectly, or under common control by such entity, or a federal,
state or local governmental body or unit or agency thereof.

“Term” has the meaning specified in Section 14 of this Agreement.

“Territory” means Canada, New Zealand, Australia, Kuwait, Tunisia, Nigeria, Thailand and
Switzerland.

“Trademarks” mean the means the registered and unregistered trade names and trade-marks used in
association with FlameOut, and listed in Schedule A to this Agreement.

	1.2	 	Interpretation

Captions and Headings. The captions and section headings used in this Agreement are for
convenience of reference only and shall not be deemed to expand, contract, alter or restrict any
term or condition herein. All references herein to sections and exhibits shall be deemed
references to such parts of this Agreement, unless the context shall otherwise require.

Gender. All references to the masculine, feminine or neuter gender, or to the singular or plural,
shall include the other as the context may require.

Exhibits and Schedules. The exhibits and schedules attached hereto are a part of this
Agreement
as if fully set forth herein.

Exhibit 10.10
– Page 2

 

 

Recitals. The recitals shall form part of this Agreement.

Currency. All dollar figures herein shall be expressed in United States dollars, unless otherwise
specified.

General. The use of the terms “including” or “include” shall in all cases mean “including, without
limitation” or “include, without limitation,” respectively. Reference to any agreement (including
this Agreement), document or instrument means such agreement, document or instrument as amended or
modified and in effect from time to time in accordance with the terms thereof and, if applicable,
the terms hereof. The use of the terms “hereunder,” “hereof,” “hereto” and words of similar import
shall refer to this Agreement as a whole and not to any particular section or clause of or exhibit
or schedule to this Agreement.

ARTICLE 2 GRANT OF LICENSE

	2.1	 	Patent License

Subject to the terms of this Agreement, Summit hereby grants to Licensee to the extent permitted by
the laws of each relevant jurisdiction, and Licensee hereby accepts from Summit:

	 	(a)	 	the limited, non-exclusive right and license to use and practice the FlameOut
Patent for the sole purpose of combining the FlameOut Bulk with water to create
FlameOut for distribution and sale in the Territory; and
	 
	 	(b)	 	the exclusive right and license to market, distribute and other exploit
FlameOut throughout the Territory.

	2.2	 	Trade-mark and Copyright License

Subject to the terms of this Agreement, Summit hereby grants to Licensee, and Licensee herby
accepts from Summit:

	 	(a)	 	the exclusive right to use the Trade-marks in association with FlameOut
throughout the Territory;
	 
	 	(b)	 	the exclusive right to sub-license the Trade-marks for use in association with
FlameOut in the territory; and
	 
	 	(c)	 	the exclusive right to use, copy, reproduce, broadcast and otherwise exploit
the copyright and other intellectual property rights in any manuals, marketing or other
materials related to FlameOut.

Exhibit 10.10
– Page 3

 

 

ARTICLE 3 MANUFACTURING, MARKETING AND DISTRIBUTION

	3.1	 	Manufacturing of FlameOut Bulk

Summit or BioGenesis shall use commercially reasonable efforts to manufacture FlameOut Bulk for
Licensee, in accordance with industry standards and government and other regulatory body
guidelines. The FlameOut Bulk shall at all times meet and exceed the quality and safety standards
prescribed by the Underwriter Labs.

Summit or BioGenesis, as the case may be, shall manufacture FlameOut Bulk in quantities to be
determined and communicated by the Licensee on a quarterly basis.

Summit shall upon request of the Licensee provide samples of FlameOut Bulk and FlameOut, free of
charge, for the purposes of marketing FlameOut to new customers.

In the event that Summit and BioGenesis are no longer able to manufacture FlameOut Bulk in
accordance with the terms of this Agreement the Licensee may practice the FlameOut Patent, or
sub-license the right to practice the FlameOut patent to the extent required to manufacture
FlameOut Bulk or contract a third party to manufacture FlameOut Bulk.

Licensee, by and through its managers, consultants and representatives, shall have the right,
during reasonable hours and upon reasonable notice to Summit or BioGenesis as the case may be, to
inspect the research, testing, development, manufacturing, marketing, sales and corporate
facilities for FlameOut Bulk. Further, the Licensee shall have the right to inspect the procedures
and protocols in the area of production, including, but not limited to, situations where demand
exceeds capacity, FlameOut is no longer meeting quality standards, or during a natural disaster.

	3.2	 	Production of FlameOut

Licensee shall blend FlameOut Bulk with water, in accordance with the instructions of Summit and
BioGenesis, as the case may be, to produce FlameOut. Such blending will take place in facilities
supplied by the Licensee.

Summit and BioGenesis, by and through their managers, consultants and representatives, shall have
the right, during reasonable hours and upon reasonable notice to Licensee to inspect the research,
testing, development, manufacturing, marketing, sales and corporate facilities where the Licensee
is blending FlameOut. Further, Summit and BioGenesis shall have the right to inspect the procedures
and protocols in the area of production, including, but not limited to, situations where demand
exceeds capacity, FlameOut is no longer meeting quality standards, or during a natural disaster.

	3.3	 	Price

Licensee shall purchase FlameOut Bulk at the price set out in Schedule B to this Agreement. Summit
may modify the prices set out in Schedule B, on a biannual basis from the Effective Date, according
to the following schedule: September 7th, 2008; March 7th, 2009; September
7th, 2009; March 7th, 2010, and so on and so forth, by providing Notice to the Licensee sixty

Exhibit 10.10
– Page 4

 

 

(60) days prior to the effective day of the price change. In no event will the price of FlameOut Bulk
increase by more than 3% in any given calendar year.

Licensee may set and adjust the retail price of FlameOut charged to its customers in its sole
discretion.

	3.4	 	Marketing

Licensee shall use commercially reasonable efforts to, during the term of this Agreement,
introduce, market, and otherwise promote the sale of FlameOut in the Territory. Licensee agrees to
devote as much time, attention and resources as may be commercially reasonable to properly conduct
such activities and to bear the entire cost and expense of conducting its activities hereunder,
including, if necessary, the maintenance of its own office space, office facilities and competent
personnel.

	3.5	 	Sales and Distribution

Licensee shall sell and distribute FlameOut in the Territory.

Beginning in the second year of the Term the Licensee and Summit may mutually agree on sales
targets for the second and subsequent years of the Agreement. Such sales targets will be based on
historical and projected sales and will be documented in writing and added to this Agreement as
Schedule D.

	3.6	 	Ordering and Payment

Licensee shall submit orders for FlameOut Bulk to Summit and/or BioGenesis, as the case may be, on
a monthly basis using an order form substantially the same as the form set out in Schedule C.
Summit or BioGenesis, as the case may be, shall provide the quantity of FlameOut ordered to the
Licensee within five (5) days of receipt of the order.

At the time of delivery of the said order Summit or BioGenesis, as the case may be, shall issue the
Licensee an invoice for the FlameOut Bulk supplied. Such invoice will be due and payable thirty
(30) days from receipt. Late payments will be subject to a fee of 1.5% monthly, with a minimum fee
of 1.5%.

	3.7	 	Reporting Obligations

Licensee shall provide to Summit, on a quarterly basis, a written report showing the amount of
FlameOut sold for the relevant quarter, including all pricing and any applicable discounts.

Exhibit 10.10
– Page 5

 

 

ARTICLE 4 OWNERSHIP AND PROTECTION OF INTELLECTUAL PROPERTY

	4.1	 	Ownership of FlameOut Patent

Licensee recognizes and acknowledges that Summit is the owner of the FlameOut Patent and all
related intellectual property. Nothing in this Agreement should be construed as a transfer of
intellectual property from any Party to Licensee other than the license rights granted herein.

	4.2	 	Ownership of Improvements

During the term of this Agreement, for the benefit of the Parties, Summit, Amiran and BioGenesis
shall use their best efforts to further develop FlameOut Bulk, and notify the Licensee of such
improvements.

In the event that the Licensee makes any improvements to the FlameOut Patent or FlameOut, the
Licensee shall promptly notify Summit of such improvements and Summit shall own such intellectual
property rights and grant a license to use and exploit such intellectual property rights to the
Licensee on the same terms as the grant of license herein.

	4.3	 	Ownership of Trade-marks

The Licensee may seek registration of the Trade-marks or any other trade-mark for use in
association with FlameOut in any country of the Territory at its own expense. The Licensee shall
own such trade-mark registrations and all associated rights and accrued good will, in accordance
with the terms of this Agreement.

	4.4	 	Protection of Intellectual Property

Licensee shall use commercially reasonable efforts to cooperate with Summit in the vigilant and
diligent protection and enforcement of Summit’s intellectual property rights including, without
limitations, any rights under the patent, copyright, trademark or trade secret law of any country
in the world.

Each Party shall promptly inform the other Parties in writing of any reasonably suspected or known
infringement of any intellectual property rights embodied in the FlameOut Patent, FlameOut,
FlameOut Bulk or any improvements thereto and the Trademarks or any other form of intellectual
property otherwise associated with FlameOut. Such notice shall, to the extent feasible, identify
the suspected or known infringing party or parties and the nature and extent of the infringement.
Summit, at its option shall prosecute all infringement and related claims that may be brought
against any Party based on or related to the aforedescribed intellectual property rights. Should
Summit choose not to prosecute a related claim, Licensee, Amiran or BioGenesis shall have the
option to prosecute said claim. The cost of such prosecution, attorneys’ fees and all litigation
related expenses, shall be borne by the Party that chose to prosecute the related claim.

Exhibit 10.10
– Page 6

 

 

ARTICLE 5 REPRESENTATIONS AND WARRANTIES

	5.1	 	Licensee Representations and Warranties

Licensee hereby represents and warrants to Summit that:

	 	(a)	 	Licensee is a corporation duly organized, validly existing and in good standing
under the laws of Canada, has all requisite power and authority to own, lease and
operate its properties and assets and to conduct its business as now being conducted.
	 
	 	(b)	 	Licensee has the corporate power and authority to enter into this Agreement and
to carry out its obligations hereunder. The execution and delivery of this Agreement
and the performance by Licensee of its obligations thereunder have been duly approved
by Licensee and no other internal corporate proceedings on the part of Licensee are
necessary to authorize such execution, delivery and performance. When this Agreement
has been duly executed by Licensee, it shall constitutes the valid and legally binding
obligation of Licensee enforceable against it in accordance with its terms.
	 
	 	(c)	 	Absence of Conflicts. The execution, delivery and performance by Licensee of
this Agreement, and the transactions contemplated herein, do not and will not conflict
with or result in any violation of or constitute a breach or default under any term of
the articles of organization or operating agreement of Licensee, of any agreement,
permit or other instrument to which Licensee is a party, or by which Licensee is bound
or any judgment to which Licensee is bound.

	5.2	 	Summit Representations and Warranties

Summit hereby represents and warrants to Licensee that:

	 	(a)	 	Summit is a corporation duly organized, validly existing and in good standing
under the laws of the State of Texas and each jurisdiction where failure to be so
qualified would be a violation of the law of such jurisdiction, has all requisite power
and authority to own, lease and operate its properties and assets and to conduct its
business as now being conducted.
	 
	 	(b)	 	Summit has the power and authority to enter into this Agreement and to carry
out its obligations hereunder and thereunder. The execution and delivery of this
Agreement and the performance by Summit of its obligations thereunder have been
approved by the Summit board of directors and no other internal proceedings on the part
of either are necessary to authorize such execution, delivery and performance. When
this Agreement has been duly executed by Summit it shall constitute the valid and
legally binding obligation of each enforceable against it in accordance with its terms.
	 
	 	(c)	 	The execution, delivery and performance by Summit of this Agreement, and the
transactions contemplated hereby and thereby, do not and will not conflict with or

Exhibit 10.10
– Page 7

 

 

	 	 	 	result in any violation of or constitute a breach or default under any term of the
operating agreement of Summit, of any agreement, permit or other instrument to which
Summit is a party, or by which Summit is bound or any judgment to which Summit is
bound.

	 	(d)	 	The FlameOut Patent is valid and owned by Summit and to the knowledge of Summit
doesn’t infringe any existing patent or other intellectual party rights of any third
party and is not the subject of any potential or existing claim(s) of infringement of
intellectual property rights.

	5.3	 	BioGenesis Representations and Warranties

BioGenesis hereby represents and warrants to Licensee that:

	 	(a)	 	BioGenesis is a corporation duly organized, validly existing and in good
standing under the laws of the State of Illinois and each jurisdiction where failure to
be so qualified would be a violation of the law of such jurisdiction, has all requisite
power and authority to own, lease and operate its properties and assets and to conduct
its business as now being conducted.
	 
	 	(b)	 	BioGenesis has the power and authority to enter into this Agreement and to
carry out its obligations hereunder and thereunder. The execution and delivery of this
Agreement and the performance by BioGenesis of its obligations thereunder have been
approved by the BioGenesis board of directors and no other internal proceedings on the
part of either are necessary to authorize such execution, delivery and performance.
When this Agreement has been duly executed by BioGenesis it shall constitute the valid
and legally binding obligation of each enforceable against it in accordance with its
terms.
	 
	 	(c)	 	The execution, delivery and performance by BioGenesis of this Agreement, and
the transactions contemplated hereby and thereby, do not and will not conflict with or
result in any violation of or constitute a breach or default under any term of the
operating agreement of BioGenesis, of any agreement, permit or other instrument to
which BioGenesis is a party, or by which BioGenesis is bound or any judgment to which
BioGenesis is bound.
	 
	 	(d)	 	The FlameOut Patent to the knowledge of BioGenesis doesn’t infringe any
existing patent or other intellectual party rights of any third party and is not the
subject of any potential or existing claim(s) of infringement of intellectual property
rights.

	5.4	 	Amiran Representations and Warranties

Amiran herby represents and warrants to Licensee that:

	 	(a)	 	The execution, delivery and performance by Amiran of this Agreement, and the
transactions contemplated hereby and thereby, do not and will not conflict with or
result in any violation of or constitute a breach or default under any term of the

Exhibit 10.10
– Page 8

 

 

	 		 	operating agreement of Amiran, of any agreement, permit or other instrument to which
Amiran is a party, or by which Amiran is bound or any judgment to which Amiran is
bound.

	 	(b)	 	The FlameOut Patent to the knowledge of Amiran doesn’t infringe any existing
patent or other intellectual party rights of any third party and is not the subject of
any potential or existing claim(s) of infringement of intellectual property rights.

ARTICLE 6 INDEMNIFICATION AND LIMITATION OF LIABILITY

	6.1	 	Licensee Indemnification

Licensee shall defend, indemnify and hold harmless Summit, its shareholders, officers, directors,
employees, agents, successors and assigns from and against all third party claims, liabilities,
fines, judgments, settlements, attorneys’ fees and other costs of litigation, arbitration or
regulatory proceeding arising out of or concerning (1) the failure of Licensee to observe and
perform any of its obligations under this Agreement, (2) any intentional or negligent act or
omission by Licensee, (3) breach of any representations or warranties by Licensee and (4) any
product liability related to the blending of FlameOut Bulk with water to create FlameOut.

Licensee’s liability in respect to 1, 2,3 above shall be limited to the amount paid for the
purchase of Flameout Bulk in the year preceding the claim. In the case of 4 the Licensee’s
liability shall be limited to the amount of it product liability coverage.

	6.2	 	Summit and BioGenesis Indemnification.

Summit, Amiran and BioGenesis shall jointly and severally defend, indemnify and hold harmless
Licensee, its officers, directors, shareholders, employees, agents, successors and assigns against
all Third Party claims, liabilities, fines, judgments, settlements, attorneys’ fees and other costs
of litigation, arbitration or regulatory proceeding arising out of or concerning (1) the failure of
either Summit, Amiran or BioGenesis to observe and perform any of its obligations under this
Agreement, (2) any intentional or negligent act or omission by Summit, Amiran or BioGenesis, and
(3) breach of any representations or warranties by Summit, Amiran and or BioGenesis, (3) any claim
of intellectual property infringement, and (4) product liability related to FlameOut Bulk.

	6.3	 	Defense of Third Party Claims

Promptly after acquiring knowledge of any claim, investigation or demand, brought by a Person that
is not a party to this Agreement (“Third Party”), to which any Party may be liable, the party
acquiring knowledge of the claim shall give prompt written notice thereof to the other party.
Thereafter, the party obligated to indemnify (“Indemnitor”) shall, at its own expense, promptly
defend, contest or otherwise protect against any Third Party claim against which it has agreed to
indemnify the party entitled to indemnification (“Indemnitee”). The Indemnitee shall give the
Indemnitor all necessary and reasonable cooperation in said defense, including, but not limited to,
the services of employees of the Indemnitee who are familiar with the subject matter or
transactions out of which any such claim, investigation or demand may have arisen. The Indemnitor
shall have the right, at its option, to compromise and settle at the Indemnitor’s

Exhibit 10.10
– Page 9

 

 

expense, any such
matter involving monetary damages but may not compromise or settle any matter involving equitable
or injunctive recourse against the Indemnitee without the Indemnitee’s written consent. The
Indemnitee, at its option and own expense, may retain additional counsel in any Third Party claim.

	6.4	 	Insurance and Product Liability

Summit, BioGenesis and the Licensee shall be responsible for each obtaining and maintaining
adequate product liability insurance, and in any case in an amount no less than two million
($2,000,000) dollars. Each party will be required to provide the other Parties, on request, with
evidence of such policy in good standing.

ARTICLE 7 CONFIDENTIAL INFORMATION, NON-COMPETE AND NON-SOLICITATION

	7.1	 	Confidentiality

In the course of the performance of this Agreement, sensitive and confidential proprietary
information and trade secrets, including but not limited to information, research, data, processes,
formulae, protocols, ingredients, technology, marketing strategies, and contacts, client lists, and
development, manufacturing, marketing, sales, and distribution information, business plans,
financial information, technical information and customer lists (“Confidential Information”) will
be disclosed by the Parties to one another. In order to facilitate the cooperation of the Parties
hereto and to protect the legitimate interests of each to their Confidential Information, the
Parties agree that the party receiving such Confidential Information under this Agreement (the
“Recipient”) will protect such Confidential Information as it would such information of its own and
may not use or disclose to any third party the Confidential Information, unless the disclosure is
in furtherance of the purpose of this Agreement and the Recipient ensures that the third party to
whom they intend to disclose the Confidential Information has agreed to be bound to terms to
protect the Confidential Information no less stringent than those herein.

This duty to protect the Confidential Information shall not apply to any information which:

	 	(a)	 	is or becomes available to the public through no fault or act of the Recipient
	 
	 	(b)	 	is obtained by Recipient from a third party under no duty of nondisclosure and
who obtained the Confidential Information by lawful means, or
	 
	 	(c)	 	is required to be disclosed pursuant to court order or subpoena, or otherwise
required by law. In the latter event, Recipient shall afford the other Parties a
reasonable opportunity to challenge such requirement prior to disclosure and to obtain
a protective order as may be available to limit or control the disclosure.

The duty to protect the Confidential Information shall survive the termination of this Agreement
regardless of the reason for termination and shall be binding upon the Parties, their successors
and assigns.

Exhibit 10.10
– Page 10

 

 

Equitable Relief. The Parties agree that the provisions and restrictions contained in this
Agreement are fair, reasonable and necessary to protect the legitimate continuing interests of the
Parties as set forth in this Agreement and that any violation or breach of these provisions may
result in irreparable injury to the Parties for which a remedy at law may be inadequate and that,
in addition to any relief at law which may be available to the Parties for such violation or
breach, and regardless of any other provision contained in this Agreement, the Parties shall be
entitled to seek injunctive and other equitable relief.

	7.2	 	Non-Competition

	 	(a)	 	Agreement Not to Compete. Summit, BioGenesis and Amiran hereby agree, jointly
and severally, that for the Term of the Agreement Summit, BioGenesis will not, without
the prior written consent of Licensee:

	 	(1)	 	directly or indirectly, through any of Summit, BioGenesis or
its Affiliates, engage in the sale or marketing of FlameOut in the Territory or
license or authorize any other Person to sell or market FlameOut in the
Territory, whether alone or as a partner, joint venturer, officer, director,
member, employee, consultant, agent, independent contractor or equity interest
holder of, or lender to, any corporation, partnership, limited liability
company, firm or other form of business organization; or
	 
	 	(2)	 	consult with, advise or assist in any way any corporation,
partnership, limited liability company, firm or other form of business
organization with respect to any of its activities or business to the extent
they compete with Licensee inside the Territory, including, but not limited to,
serving as an intermediary for any such competing enterprise, loaning money or
rendering any other form of financial assistance to or engaging in any form of
business transaction on other than an arm’s length basis with any such
competing enterprise, in each case with respect to its activities or business
to the extent they compete with the Licensee inside the Territory.

	 	(b)	 	Amiran will not, for the Term of this Agreement, without the prior written
consent of Licensee:

directly or indirectly, engage in the sale or marketing of FlameOut in the Territory
or license or authorize any other Person to sell or market FlameOut in the
Territory, whether alone or as a partner, joint venturer, officer, director,
member, employee, consultant, agent, independent contractor or equity interest
holder of, or lender to, any corporation, partnership, limited liability
company, firm or other form of business organization; or

consult with, advise or assist in any way any corporation, partnership, limited
liability company, firm or other form of business organization with respect to
any of its activities or business to the extent they compete with Licensee
inside the Territory, including, but not limited to, serving as an intermediary
for any such competing enterprise, loaning money or

Exhibit 10.10
– Page 11

 

 

rendering any other form of
financial assistance to or engaging in any form of business transaction on
other than an arm’s length basis with any such competing enterprise, in each
case with respect to its activities or business to the extent they compete with
the Licensee inside the Territory.

Licensee hereby agrees that for the period beginning on the Effective Date and ending upon
the third anniversary after the termination of the Agreement, for any reason (the
“Restricted Period”) Licensee will not, without the prior written consent of Summit:

consult with, advise or assist in any way any corporation, partnership, limited
liability company, firm or other form of business organization with respect to
any of its activities or business to the extent they compete with Summit or
BioGenesis outside the Territory, including, but not limited to, serving as an
intermediary for any such competing enterprise, loaning money or rendering any
other form of financial assistance to or engaging in any form of business
transaction on other than an arm’s length basis with any such competing
enterprise, in each case with respect to its activities or business to the
extent they compete with Summit or BioGenesis outside the Territory.

Non-Solicitation

Covenant Not to Solicit Employees. Summit and BioGenesis and each of their Affiliates hereby
agree, jointly and severally, that, for a period of three (3) years from and after the
date of termination of this Agreement, for any reason, such Party or Affiliate shall
not, directly or indirectly through any of such Party or an Affiliate:

solicit for employment or other working arrangement (e.g., independent contracting)
any employee or then currently active independent contractor of Licensee, or
person who was an employee or currently active independent contractor of
Licensee or any of its Affiliates within the six (6) month period immediately
preceding such solicitation, or

induce or attempt to induce any employee or independent contractor of Licensee to
terminate his or her employment or contracting relationship with Licensee, in
each case other than pursuant to a general solicitation or advertisement for
employment.

Summit and BioGenesis and each of their Affiliates hereby agree, jointly and severally,
that, for a period of one (1) year from and after the date of termination of this
Agreement, for any reason, such Party and each Affiliate, as the case may be, shall
not, directly or indirectly through the Party or an Affiliate:

Exhibit 10.10
– Page 12

 

 

induce or attempt to induce any Person to patronize any enterprise that is directly
or indirectly in competition with Licensee;

canvass, solicit or accept from any Person any such competitive business in the
Territory; or

request or advise any Person to withdraw, curtail or cancel any such customer’s
business with Licensee in Territory.

Licensee hereby agrees that, for a period of one (1) year from and after the date of
termination of this Agreement, for any reason or for no reason, such Licensee and its
Affiliates, as the case may be, shall not, directly or indirectly through the Licensee
or an Affiliate:

induce or attempt to induce any Person to patronize any enterprise that is directly
or indirectly in competition with Summit;

canvass, solicit or accept from any Person any such competitive business outside the
Territory; or

request or advise any Person to withdraw, curtail or cancel any such customer’s
business with Licensee outside the Territory.

TERM AND TERMINATION

Term and Termination

Term. This Agreement shall be effective on the Effective Date, and shall continue in effect for a
period of ten (10) years, unless earlier terminated pursuant to this Agreement (the “Term”).

Option. Provided that Licensee is not in material default under this Agreement on the last day of
the Term, Licensee shall have the option (“Option”) to renew this Agreement for four (4) additional
terms of five (5) years each (“Option Term”). This Agreement will be automatically renewed unless
Licensee opts out of the Agreement by giving written notice to Summit not less than one hundred
eighty (180) days prior to the termination of the initial Term or any subsequent additional term.

Early termination. Notwithstanding the term of this Agreement this Agreement may be earlier
terminated upon written notice:

by the non-breaching Party if a Party breaches any material non monetary covenant
or provision of this Agreement, and such Party fails to cure such breach within ninety
(90) days of receiving written notice thereof; or

either Party becomes insolvent or if there are any proceedings instituted by or against
either party in bankruptcy or under insolvency laws or for reorganization,

Exhibit 10.10
– Page 13

 

 

receivership
or dissolution, or if either Party shall make an assignment for the benefit of
creditors If the Agreement is properly terminated pursuant to this section, the
non-competition and non-solicitation clauses set forth in Sections 7.2 (a), (b) and 7.3
(a) and (b) shall not apply.

Effects of termination. Any termination of this Agreement above shall not relieve either party of
its obligation accrued prior to the termination of this Agreement or any obligation that is
intended to survive the termination of this Agreement. Termination of this Agreement shall not
affect, preclude, reduce or limit any other remedy at law or in equity that may be available to
either Party. Upon the termination of this Agreement for any reason, including, without limitation,
upon the expiration of the Term or the mutual agreement of the Parties:

	 	(a)	 	within ten (10) days, the Recipients of the Confidential Information shall
deliver to the disclosing party all Confidential Information;

Licensee shall cease the use of FlameOut Bulk and the marketing, distribution and sale of
FlameOut and the use of any Confidential Information or other intellectual property
associated with FlameOut or the FlameOut Patent; and

Licensee shall assign and transfer any trade-mark registrations or applications for the
trade-mark FLAMEOUT in the Territory to Summit in exchange for payment by Summit of an
amount equivalent to the costs incurred or paid for registration of such trade-mark.

MISCELLANEOUS PROVISIONS

Severability

In the event a court of competent jurisdiction or arbitrator determines that the provisions of this
Agreement are excessively broad as to duration, geographical scope or activity, it is expressly
agreed that this Agreement shall be construed so that the remaining provisions hereof shall not be
affected by any such determination, but shall remain in full force and effect, and any such
overbroad provisions shall be deemed, without further action on the part of any party, to be
modified, amended and/or limited, but only to the extent necessary to render the same valid and
enforceable in such jurisdiction.

Remedies

Licensee acknowledges that violation of any of the provisions of this Agreement will cause
irreparable loss and harm to Summit, which cannot be reasonably or adequately compensated by
damages in an action at law. Accordingly, in the event of a breach or threatened breach by Licensee
of any of the provisions of this Agreement, the Summit will be entitled, without posting bond or
other security, to injunctive and other equitable relief to prevent or cure any breach or
threatened breach thereof, and Licensee agrees that it will not be a defense to any request for
such relief that the Summit has an adequate remedy at law. Notwithstanding the foregoing, the

Exhibit 10.10
– Page 14

 

 

Summit shall have other legal remedies as may be appropriate under the circumstance including,
inter alia, recovery of damages occasioned by such breach.

Damages

Provided that Licensee is not in default under the terms of this Agreement, in the event that
Summit shall enter into a license agreement with a Person other than Licensee for the marketing and
sale of FlameOut in the Territory, then Licensee shall be entitled to one hundred percent (100%) of
all income or fees of Summit resulting from such license of FlameOut.

Force Majeure

A Party (“the Excused Party”) shall be excused from any performance owed to the other Party
hereunder if such performance is rendered impossible by acts of state or governmental action,
riots, disturbances, war, strikes, lockouts, slowdowns, prolonged shortages of energy or supplies,
epidemics, fire, flood, storm, earthquake, lightning or explosion. The periods of any such excused
performance shall be limited to such time as such circumstances exist, plus ninety (90) days. The
Excused Party shall give prompt written notice to the other Party of any such circumstances and of
the anticipated time when such performance will be resumed by the Excused Party. The Excused Party
shall also give prompt written notice to the other Party of the cessation of such circumstances and
the resumption of performance by the Excused Party.

Notices

All notices, requests and other communications to any party hereunder shall be in writing, shall be
given to such party at its address set forth below or at such other address as shall be furnished
by any party by like notice to the others. Each such notice, request or other communication shall
be deemed to have been duly given (i) as of the date of delivery, if delivered personally, (ii)
upon the next Business Day when delivered during normal business hours to a recognized overnight
courier service, such as Federal Express, or (iii) on the date of delivery or refusal shown on the
return receipt therefore if sent by United States certified or registered mail, return receipt
requested and postage prepaid.

If to Summit:

Summit Environmental Corporation, Inc

Attentions: Mohsen C. Amiran, PhD, Executive Vice President

610 W. Rawson Ave

Oak Creek, WI 53154

with a copy to:

Thomas J. Kenan, Esq.

Fuller Tubb Bickford & Krahl

201 Robert S. Kerr Ave. Suite 1000

Oklahoma City, OK 73102

Exhibit 10.10
– Page 15

 

 

If to BioGenesis:

BioGenesis

Attentions: Charles Wilde, Vice President

7420 Alban Station Blvd, Suite B-208

Springfield, VA 22150

If to Amiran:

Mohsen C. Amiran

308 S. Mt. Prospect Rd,

Des Plaines, IL 60016

If to Licensee:

Just-In Case Fire Ltd.

Attention: Mark Hayes

321 11979 — 40th St SE ,

Calgary, Alberta Canada T2Z 4M3

with a copy to:

Borden Ladner Gervais LLP

Attention: LuAnne Morrow

1000, 400 3 Ave SW

Calgary, Alberta T2P 4H2

or such other alternative addresses or persons as the Parties may from time to time designate in
writing to each of the parties.

Maintenance of Books and Records, and Accounting.

Licensee shall, at all times, keep and maintain complete and accurate books and records of all
transactions in connection with its business operations, and sales of FlameOut including the
identity of all purchasers of FlameOut, and the identity and quantity of all FlameOut sold for a
period of at least five (5) years after the period with respect to which such books and records
pertain.

Successors and Assigns.

This Agreement shall inure to the benefit of, and be binding upon, the Parties hereto and their
respective successors, heirs, representatives and permitted assigns, as the case may be; provided,
however, that the Licensee shall not assign or delegate this Agreement or any of the rights or
obligations created hereunder except as provided for in this Agreement.

Exhibit 10.10
– Page 16

 

 

Independent Parties.

Nothing in this Agreement constitutes a partnership between or joint venture by the Parties hereto
or constitutes either Party as the agent of the other. Neither Party shall hold itself out contrary
to the terms of this subparagraph (c), and neither Party shall become liable by any representation,
act or omission of the other Party, which is contrary to the terms of this Section.

Entire Agreement:

Amendment. This Agreement, including any exhibits, schedules or other attachments hereto,
constitutes the entire Agreement between the parties hereto and supersedes and cancels any and all
prior or contemporaneous negotiations, undertakings, discussions or agreements between the Parties.

Governing Law

This Agreement shall be governed by the laws of the province of Alberta and the federal laws of
Canada applicable therein.

Waivers, Amendments and Remedies.

This Agreement may be amended and the terms hereof may be waived, and consents may be provided,
only by a written instrument signed by Summit and Licensee or, in the case of a waiver, by the
Party waiving compliance. No delay on the part of any Party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof; nor shall any waiver on the part of any
Party of any such right, power or privilege, nor any single or partial exercise of any such right,
power or privilege, preclude any further exercise thereof or the exercise of any other such right,
power or privilege. The rights and remedies herein provided are cumulative and are not exclusive
of any rights or remedies that any Party may otherwise have at law or in equity. The rights and
remedies of any Party based upon, arising out of or otherwise in respect of any breach of any
representation, warranty or covenant contained in this Agreement shall in no way be limited by the
fact that the act, omission, occurrence or other statement of facts upon which any claim of any
such breach is based may also be the subject matter of any other representation, warranty or
covenant contained in this Agreement (or in any other agreement among the Parties) as to which
there is no breach.

Publicity

The parties shall have no right to use another Party’s name, likeness and/or other information
relating to either Party in any promotional or other material produced by or on behalf of either
Party without that Party’s prior written approval.

Counterparts.

This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original and all of which together shall be considered one and the same agreement.

Exhibit 10.10
– Page 17

 

 

     IN WITNESS WHEREOF the Parties hereto have duly executed this Agreement as of the day and year
first written above.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	SUMMIT ENVIRONMENTAL CORPORATION INC.	 	 	 	BIOGENESIS ENTERPRISES INC.	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Per:
	 	/s/ Mohsen C. Amiran	 	 	 	Per:	 	/s/ Charles Wilde	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Per:
	 	Mohsen C. Amiran	 	 	 	Per:	 	Charles Wilde	 	 	 	 
	 
	 	Vice President	 	 	 	 	 	Vice President	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	JUST-IN CASE FIRE LTD.	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Per:
	 	/s/ Mark Hayes	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Per:
	 	Mark Hayes	 	 	 	 	 	 	 	 	 	 
	 
	 	President	 	 	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	SIGNED, SEALED AND
DELIVERED by
DR. MOHSEN C. AMIRAN PHD in the

presence of:	 		 		 	 	 	 
	 
	 	 	 	)	 	 	 	 	 	 	 	 
	/s/ Sherwin C. Amiran	 	)	 	
    /s/ Mohsen C. Amiran	 	 	 	 
	 
	 	 	 	)	 	 	 	 	 	 	 	 
	 	 	)	 	 	 	 	 	 
	 
	 	 	 	)	 	 	 	 	 	 	 	 
	Name:
	 	Sherwin C. Amiran	 	)	 	DR.	 	MOHSEN C. AMIRAN	 	 	 	 
	Address: 
	 	610 Rawson Avenue	 	)	 	 	 		 	 	 	 
	 
	 	Oak Creek, WI  53154	 	)	 	 	 		 	 	 	 
	 
	 		 	 	 	 	 		 	 	 	 
	Occupation: 
	 	Assistant Director	 	 	 	 	 		 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 

 

Exhibit 10.10
– Page 18

 

SCHEDULE A

TRADE-MARKS

	 	 	 	 	 
	Trade-mark	 	Registration/Application #	 	Jurisdiction
	FLAMEOUT
	 	2294147
	 	United States of America

Exhibit 10.10
– Page 19

 

 

SCHEDULE B

PRICE

	 	 	 
	Quantity Purchased	 	Price
	50,000-25,000
	 	$7.58 (275 Gallon Totes)
	25,000-10,000
	 	$7.96 (275 Gallon Totes)
	10,000-5,000
	 	$8.40 (275 Gallon Totes or 55 Gallon Drums)
	5,000-1,000
	 	$8.69 (275 Gallon Totes or 55 Gallon Drums)

$8.99 (5 Gallon Jugs)
	1,000-275
	 	$8.82 (275 Gallon Totes or 55 Gallon Drums)

$9.12 (5 Gallon Jugs)
	275-0
	 	$11.00 (5 Gallon Jugs)

Exhibit 10.10
– Page 20

 

 

SCHEDULE C

ORDER FORM

Exhibit 10.10
– Page 21

 

 

SCHEDULE D

SALES TARGETS

Exhibit 10.10
– Page 22exv10w34

 

Exhibit
10.34

 

Plan: FY08 Executive Incentive Plan

Division: Corporate

	I.	 	Objective

Thoratec’s Executive Incentive Plan, hereinafter referred to as EIP is intended to reward
executive personnel who significantly impact and influence Thoratec’s productivity in
proportion to their accomplishment of specified objectives.
	 
	 	 	The purpose of the plan is to ensure maximum return to Thoratec by encouraging greater
initiative, resourcefulness, teamwork and efficiency on the part of senior management whose
performance and responsibilities directly affect company profits.
	 
	 	 	Awarding of the bonus will be based on accomplishing a set of annual objectives, determined
by the Chief Executive Officer (“CEO”) and the Board of Directors, typically at the
beginning of the year. Bonus determinations and payouts will take place after the financial
statements have been prepared for the fiscal year.
	 
	II.	 	Determination Of The Fund

The availability of, and participants in, the fund will be set by the CEO and approved by
the Board of Directors as part of the annual budgeting process.
	 
	III.	 	Effective Date

The effective date of this program is December 30, 2007, the beginning of the plan year, and
will continue in effect until January 3, 2009, or until terminated or amended by the Board
of Directors. This plan supersedes all prior EIP plans.
	 
	IV.	 	Eligibility

Participation in the plan is limited to Officers and others in comparable levels of
responsibility who have a direct and significant influence on Thoratec’s growth and
profitability. Employees must be regular and not eligible for any other Thoratec commission,
bonus or incentive plan in order to be eligible to participate in the EIP.
	 
	 	 	Participating employees will be determined at the beginning of the fiscal year, or at such
time during the Fiscal Year that an employee achieves an eligible position. Employees will
be notified of their eligibility and plan objectives, as soon as possible after the
determination by the CEO or Board of Directors.
	 
	 	 	Individuals must be employed by Thoratec at the close of the fiscal year and on the date of
payment in order to be eligible for an award under the EIP except participants who are
involuntarily terminated due to a divestiture, plant closing, reorganization or reduction in
force during the plan year may receive an award on the prorated basis described in Section
VIII, Plan Administration, Prorated Awards, [subject to approval by the CEO]. These monies
will be paid out at the usual and customary time of payment of all bonuses. For purposes of
this plan, termination shall mean the day the employee leaves the job, which may not
necessarily be the last day on the payroll.
	 
	V.	 	Incentive Objectives

Objectives will be agreed to by the CEO with the Executive Officers reporting to him and
with concurrence by the Board of Directors as necessary. Generally, there will be a minimum
of four up to a maximum of seven objectives, which will include two or more corporate
financial objectives. Each objective will be weighted according to its importance, which
weight will determine the percentage of the bonus awarded for completion of that objective.
(See Section VI below.)
	 
	VI.	 	Bonus Opportunity and Award

The award opportunity will be expressed as a percentage of the participant’s base salary at
the close of the fiscal year.

1

 

The award will be approved by the Board of Directors or the
CEO, and will be consistent with the participant’s peers within
the company.

The amount that a participant actually receives for the full fiscal year will be based upon
the extent to which the set objectives have been achieved. The participant will receive a
percentage of the total award opportunity corresponding to the percentage of each objective
accomplished and the weight assigned to the objective. Evaluations of performance against
management and business plan objectives are made for the full year prior to fiscal year-end
payment.

	VII.	 	Performance Goal and Payout

In addition to your individual goals, everyone will have two company-oriented financial
goals that will be achieved according to the following guidelines:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	           (1)
	 	 	Revenue	 	Non-GAAP Income Before Tax
	 	 	Goal	 	Award	 	Goal	 	Award
	 	 	 
	Threshold = to, or >
	 	$	*	 	 	 	50	%	 	$	*	 	 	 	50	%
	Target = to, or >
	 	$	*	 	 	 	100	%	 	$	*	 	 	 	100	%

Note: If revenue is less than $* (95% of target), no payment is earned for that objective.
If consolidated NGIBT earnings is less than $* (90% of target), no payment is earned for
that objective. If actual results fall between threshold and target, interpolate between
them to get actual payout percentage. This percentage will be multiplied times the weight
given the objective in your individual plan to determine the achievement. Quarterly revenue
and NGIBT earnings information may be released at the end of each quarter, after earnings
have been disclosed to the public.

	 	(1)	 	NGIBT earnings is defined as consolidated GAAP net income before taxes excluding, as
applicable, amortization of intangibles, in-process R&D, impairment of intangibles, certain
litigation, restructuring and CEO transition expenses and other unusual or non-recurring
costs, and also excluding share-based compensation expense under SFAS No. 123R and changes
in the value of the “make-whole” provision of our convertible notes and special incentive
awards.

	VIII.	 	Over-Achievement Award Opportunity/Performance Accelerator

In addition, each EIP participant will receive a [x]*% increase for every [y]*% increase in
consolidated NGIBT earnings over the target level. For example, if you earned 85% of your
total objectives for the year, and the company made $* of NGIBT earnings (a *%
over-achievement), with a base salary of $50,000 and a bonus target of 20%, your award would
be calculated as follows:

	 
	 	 	Annualized base salary ($50,000) x target bonus (20%) x

(30% financial and 55% individual accomplishment for 85% total) x 1.* = $*

	 
	IX.	 	Plan Administration

Prorated Awards. Individuals who are promoted to eligible positions during the plan
year, new hires into eligible positions and eligible employees who are either on
leave or on active written warning for part of the year may be awarded partial bonuses
under this program, based on the accomplished objectives and their respective weights,
subject to the approval of the CEO.
	 
	 	 	Transfers. In the event of transfer of an eligible participant to another position or
department, the transferring manager will evaluate EIP results for prorated award (see
Prorated Awards above) at the end of the year, and forward to the Human Resources
Department. The hiring manager will be responsible for setting the key business plan
objectives for the balance of the year, if applicable, and forwarding to Human Resources for
approval. Awards based on these objectives will be prorated (see Prorated Awards above) as
well, for end of the year payment.
	 
	 	 	Authority. The Board of Directors shall have the full power and authority to construe,
interpret and administer the plan. All decisions, actions or interpretations of the Board
of Directors shall be final and conclusive and binding on all
parties. This program shall be administered by the Human Resources Department.

 

			
	*	 	Amounts and percentages to be determined by the Compensation and
Option Committee of the Board of Directors.

2

 

	 
	X.	 	General Provisions

	 	•	 	The Executive Incentive Plan for 2008 may be reviewed and revised at the Board’s
discretion.
	 
	 	•	 	Nothing in this plan shall be construed to limit in any way the right of Thoratec
Corporation to terminate an employee’s employment at any time, with or without cause or
notice, nor shall it be evidence of any agreement or understanding, expressed or
implied, that Thoratec or any of its subsidiaries will employ an employee in any
particular position, for any particular period of time, ensure participation in any
incentive programs, or the granting of awards from such programs as they may from time
to time exist or be constituted. Thoratec reserves the right to discontinue or alter
the plan at its sole discretion at any time with or without notice.

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]